ELVN Enliven Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1672619 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.7%
TTM EPS YoY6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-16.8%
ROA-16.4%
ROIC (approx.)-19.4%
Asset turnover—
Leverage & solvency
Liabilities / assets2.3%
Debt / equity0.00x
Current ratio45.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $85.86M | $80.78M | $64.57M | $31.02M | $38.44M |
| SG&A expense | $33.80M | $23.78M | $18.95M | $7.77M | $13.00M |
| Operating income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$51.44M |
| Pretax income | — | — | — | $1.58M | -$51.38M |
| Income tax | $0 | $232,000 | $0 | $0 | — |
| Net income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$51.38M |
| EBITDA | -$119.36M | -$104.25M | -$83.23M | -$38.59M | -$51.34M |
| EPS (basic) | -1.83 | -1.89 | -2.01 | -12.05 | -2.37 |
| EPS (diluted) | -1.83 | -1.89 | -2.01 | -12.05 | -2.37 |
| Weighted avg. shares (diluted) | 56.66M | 47.07M | 35.55M | 3.12M | 21.66M |
| Balance sheet | |||||
| Cash & equivalents | $98.90M | $124.17M | $100.19M | $75.59M | $110.08M |
| Short-term investments | $363.73M | $189.32M | $153.01M | $0 | $41.97M |
| Current assets | $474.88M | $318.13M | $266.15M | $77.75M | $92.70M |
| PP&E, net | $34,000 | $458,000 | $742,000 | $890,000 | $250,000 |
| Total assets | $476.17M | $325.76M | $271.87M | $83.30M | $93.65M |
| Current liabilities | $16.57M | $15.91M | $25.89M | $9.71M | $7.21M |
| Total liabilities | $16.57M | $15.91M | $25.96M | $10.37M | $7.62M |
| Shareholders' equity | $459.60M | $309.85M | $245.91M | -$76.83M | -$42.89M |
| Shares outstanding | 59.44M | 48.94M | 41.29M | 3.57M | 26.29M |
| Cash flow statement | |||||
| Operating cash flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | -$46.77M |
| Capital expenditure | $158,000 | $44,000 | $149,000 | $612,000 | $12,000 |
| Free cash flow | -$70.46M | -$73.24M | -$61.42M | -$32.69M | -$46.78M |
| Investing cash flow | -$173.84M | -$36.00M | -$148.41M | -$612,000 | -$1.63M |
| Financing cash flow | $218.87M | $133.16M | $234.29M | -$1.80M | $49.10M |
| Depreciation & amortization | $300,000 | $300,000 | $300,000 | $200,000 | $99,000 |
| Stock-based compensation | $34.02M | $20.17M | $12.91M | $3.19M | $3.85M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.